![Kazuhiro Sumigama](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Kazuhiro Sumigama worked as the Chief Executive Officer at Yasuda Enterprise Development Co. Ltd. from 2017 to 2018.
Anciens postes connus de Kazuhiro Sumigama
| Sociétés | Poste | Fin |
|---|---|---|
Yasuda Enterprise Development Co. Ltd.
 Yasuda Enterprise Development Co. Ltd. Investment ManagersFinance YED invests in early- and expansion-stages businesses in Asia, Europe and the US, across sectors including ICT, electronics devices and life sciences. Their investment strategy focuses on growing companies across expansion stages and with IPO and M&A potential. The firm invests in companies based on distinctive technology, favoring start-up and early-stage businesses. YED targets emerging firms with cutting edge technology in the medical device and biotechnology area, as well as in the IT sector. They focus on Japan, the US, Taiwan and Europe and favor businesses with the potential to penetrate global markets. The firm's preferred type of financing includes direct equity, convertible bonds and warrants. | Directeur Général | 31/08/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
1
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Yasuda Enterprise Development Co. Ltd.
Yasuda Enterprise Development Co. Ltd. Investment ManagersFinance YED invests in early- and expansion-stages businesses in Asia, Europe and the US, across sectors including ICT, electronics devices and life sciences. Their investment strategy focuses on growing companies across expansion stages and with IPO and M&A potential. The firm invests in companies based on distinctive technology, favoring start-up and early-stage businesses. YED targets emerging firms with cutting edge technology in the medical device and biotechnology area, as well as in the IT sector. They focus on Japan, the US, Taiwan and Europe and favor businesses with the potential to penetrate global markets. The firm's preferred type of financing includes direct equity, convertible bonds and warrants. | Finance |
